US1055321053 - ADR

Overall **BAK** gets a fundamental rating of **1** out of 10. We evaluated **BAK** against 85 industry peers in the **Chemicals** industry. **BAK** may be in some trouble as it scores bad on both profitability and health. **BAK** does not seem to be growing, but still is valued expensively.

In the past year **BAK** has reported a negative cash flow from operations.

In multiple years **BAK** reported negative net income over the last 5 years.

In the past 5 years **BAK** always reported a positive cash flow from operatings.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -5.12% | ||

ROE | -93.87% | ||

ROIC | N/A |

ROA(3y)2.32%

ROA(5y)1.54%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

In the last couple of years the **Operating Margin** of **BAK** has declined.

In the last couple of years the **Gross Margin** of **BAK** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 2.66% |

OM growth 3Y-5.67%

OM growth 5Y-20.61%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.5%

GM growth 5Y-14.73%

The number of shares outstanding for **BAK** remains at a similar level compared to 1 year ago.

The number of shares outstanding for **BAK** remains at a similar level compared to 5 years ago.

Based on the Altman-Z score of **0.98**, we must say that **BAK** is in the distress zone and has some risk of bankruptcy.

A Debt/Equity ratio of **10.77** is on the high side and indicates that **BAK** has dependencies on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 10.77 | ||

Debt/FCF | N/A | ||

Altman-Z | 0.98 |

ROIC/WACCN/A

WACC8.94%

Looking at the **Current ratio**, with a value of **1.54**, **BAK** is doing worse than **74.12%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.54 | ||

Quick Ratio | 1.03 |

The Revenue for **BAK** has decreased by **-31.09%** in the past year. This is quite bad

EPS 1Y (TTM)-333.36%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-119.57%

Revenue 1Y (TTM)-31.09%

Revenue growth 3Y22.64%

Revenue growth 5Y14.4%

Revenue growth Q2Q-34.31%

The **Earnings Per Share** is expected to grow by **83.56%** on average over the next years. This is a very strong growth

The **Revenue** is expected to decrease by **-5.53%** on average over the next years.

EPS Next Y-1058.25%

EPS Next 2Y-118.08%

EPS Next 3Y83.56%

EPS Next 5YN/A

Revenue Next Year-27.78%

Revenue Next 2Y-12.29%

Revenue Next 3Y-5.53%

Revenue Next 5YN/A

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

Also next year **BAK** is expected to report negative earnings again, which makes the also the **Forward Price/Earnings** Ratio negative.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **BAK** indicates a slightly more expensive valuation: **BAK** is more expensive than 60.00% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | 16.48 |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-118.08%

EPS Next 3Y83.56%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**BRASKEM SA-CLASS A- ADR**

NYSE:BAK (2/23/2024, 7:04:00 PM)

After market: 8.2 +0.02 (+0.24%)**8.18**

**-0.16 (-1.92%) **

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.26B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -5.12% | ||

ROE | -93.87% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 2.66% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.79

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 10.77 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.54 | ||

Quick Ratio | 1.03 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-333.36%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-1058.25%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-31.09%

Revenue growth 3Y22.64%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y